1,210
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

Validity of fatty liver disease indices in the presence of alcohol consumption

ORCID Icon, , , , , , , , , , & ORCID Icon show all
Pages 1349-1360 | Received 13 Apr 2022, Accepted 27 May 2022, Published online: 18 Jun 2022

References

  • Kim D, Li AA, Gadiparthi C, et al. Changing trends in etiology-based annual mortality from chronic liver disease, from 2007 through 2016. Gastroenterology. 2018;155(4):1154–1163.e3.
  • Younossi ZM. Non-alcoholic fatty liver disease – a global public health perspective. J Hepatol. 2019;70(3):531–544.
  • Carr RM, Oranu A, Khungar V. Nonalcoholic fatty liver disease. Gastroenterol Clin North Am. 2016;45(4):639–652.
  • EASL– E. Clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–402.
  • Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209.
  • Åberg F, Färkkilä M. Drinking and obesity: alcoholic liver disease/nonalcoholic fatty liver disease interactions. Semin Liver Dis. 2020;40(02):154–162.
  • Younossi ZM, Stepanova M, Ong J, et al. Effects of alcohol consumption and metabolic syndrome on mortality in patients with nonalcoholic and alcohol-related fatty liver disease. Clin Gastroenterol Hepatol. 2019;17(8):1625–1633.e1.
  • Zelber-Sagi S, Sheron N, Hydes T. Policy Statement on the Coexistence of Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol-Related Liver Disease (ARLD) 2020. Accessed January 18, 2022. https://easl.eu/wp-content/uploads/2020/08/Full-version-Policy-Statement-on-the-coexistence-of-NAFLD-and-ARLD_26Aug2020.pdf.
  • Berzigotti A, Tsochatzis E, Boursier J, et al. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. Journal of Hepatology. 2021;75(3):659–689.
  • Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American gastroenterological association, American association for the study of liver diseases, and American college of gastroenterology. Gastroenterology. 2012;142(7):1592–1609.
  • Bedogni G, Bellentani S, Miglioli L, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6(1):33.
  • Ruhl CE, Everhart JE. Fatty liver indices in the multiethnic United States national health and nutrition examination survey. Aliment Pharmacol Ther. 2015;41(1):65–76.
  • Cuthbertson DJ, Weickert MO, Lythgoe D, et al. External validation of the fatty liver index and lipid accumulation product indices, using 1H-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals. Eur J Endocrinol. 2014;171(5):561–569.
  • Koehler EM, Schouten JNL, Hansen BE, et al. External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. Clin Gastroenterol Hepatol. 2013;11(9):1201–1204.
  • Shen YN, Yu MX, Gao Q, et al. External validation of non-invasive prediction models for identifying ultrasonography-diagnosed fatty liver disease in a Chinese population. Medicine. 2017;96(30):e7610.
  • Fedchuk L, Nascimbeni F, Pais R, et al. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2014;40(10):1209–1222.
  • Meffert PJ, Baumeister SE, Lerch MM, et al. Development, external validation, and comparative assessment of a new diagnostic score for hepatic steatosis. Am J Gastroenterol. 2014;109(9):1404–1414.
  • Zelber-Sagi S. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. WJG. 2013;19(1):57.
  • Yang BL, Wu WC, Fang KC, et al. External validation of fatty liver index for identifying ultrasonographic fatty liver in a large-scale cross-sectional study in Taiwan. PLoS ONE. 2015;10(3):e0120443.
  • Kim JH, Kwon SY, Lee SW, et al. Validation of fatty liver index and lipid accumulation product for predicting fatty liver in Korean population. Liver Int. 2011;31(10):1600–1601.
  • Xia MF, Yki-Järvinen H, Bian H, et al. Influence of ethnicity on the accuracy of non-invasive scores predicting non-alcoholic fatty liver disease. PLoS ONE. 2016;11(8):e0160526.
  • Dai H, Wang W, Chen R, et al. Lipid accumulation product is a powerful tool to predict non-alcoholic fatty liver disease in Chinese adults. Nutr Metab (Lond). 2017;14(1):49.
  • Almeida NS, Rocha R, Cotrim HP, et al. Anthropometric indicators of visceral adiposity as predictors of non-alcoholic fatty liver disease: a review. World J Hepatol. 2018;10(10):695–701.
  • McHenry S, Park Y, Browning JD, et al. Dallas steatosis index identifies patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2020;18(9):2073–2080.e7.
  • Juonala M, Viikari JSA, Raitakari OT. Main findings from the prospective cardiovascular risk in young Finns study. Curr Opin Lipidol. 2013;24(1):57–64.
  • Bamberg F, Hetterich H, Rospleszcz S, et al. Subclinical disease burden as assessed by whole-body MRI in subjects with prediabetes, subjects with diabetes, and normal control subjects from the general population: the KORA-MRI study. Diabetes. 2017;66(1):158–169.
  • Holle R, Happich M, Löwel H, et al. KORA - a research platform for population based health research. Gesundheitswesen. 2005;67(S 01):19–25.
  • Raitakari OT, Juonala M, Ronnemaa T, et al. Cohort profile: the cardiovascular risk in young Finns study. Int J Epidemiol. 2008;37(6):1220–1226.
  • Suomela E, Oikonen M, Pitkänen N, et al. Childhood predictors of adult fatty liver. The cardiovascular risk in young Finns study. J Hepatol. 2016;65(4):784–790.
  • Edens MA, van Ooijen PMA, Post WJ, et al. Ultrasonography to quantify hepatic fat content: validation by 1H magnetic resonance spectroscopy. Obesity. 2009;17(12):2239–2244.
  • Caussy C, Reeder SB, Sirlin CB, et al. Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials. Hepatology. 2018;68(2):763–772.
  • Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7):503–508.
  • Lazarus J v, Mark HE, Villota-Rivas M, et al. The global NAFLD policy review and preparedness index: are countries ready to address this silent public health challenge? J Hepatol. Published Online. December 2021;76(4):771–780.
  • McPherson S, Hardy T, Henderson E, et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015;62(5):1148–1155.
  • Perumpail BJ, Khan MA, Yoo ER, et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017;23(47):8263–8276.
  • Niezen S, Trivedi HD, Mukamal KJ, et al. Associations between alcohol consumption and hepatic steatosis in the USA. Liver Int. 2021;41(9):2020–2023.
  • Long MT, Massaro JM, Hoffmann U, et al. Alcohol use is associated with hepatic steatosis among persons with presumed nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2020;18(8):1831–1841.e5.
  • Traversy G, Chaput JP. Alcohol consumption and obesity: an update. Curr Obes Rep. 2015;4(1):122–130.
  • Åberg F, Puukka P, Salomaa V, et al. Risks of light and moderate alcohol use in fatty liver disease: follow-up of population cohorts. Hepatology. 2020;71(3):835–848.
  • Nivukoski U, Niemelä M, Bloigu A, et al. Combined effects of lifestyle risk factors on fatty liver index. BMC Gastroenterol. 2020;20(1):109.
  • Åberg F, Helenius-Hietala J, Puukka P, et al. Binge drinking and the risk of liver events: a population-based cohort study. Liver Int. 2017;37(9):1373–1381.
  • Sahlman P, Nissinen M, Puukka P, et al. Genetic and lifestyle risk factors for advanced liver disease among men and women. J Gastroenterol Hepatol. 2020;35(2):291–298.
  • Hart CL, Morrison DS, Batty GD, et al. Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studies. BMJ. 2010;340(mar11 1):c1240–c1240.
  • Åberg F, Puukka P, Salomaa V, et al. Combined effects of alcohol and metabolic disorders in patients with chronic liver disease. Clin Gastroenterol Hepatol. 2020;18(4):995–997.e2.
  • Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274–285.
  • Danielsson O, Nissinen MJ, Jula A, et al. Waist and hip circumference are independently associated with the risk of liver disease in population‐based studies. Liver Int. 2021;41(12):2903–2913.
  • Iwasaki Y, Shiina K, Matsumoto C, et al. Correlation of the fatty liver index with the pathophysiological abnormalities associated with cardiovascular risk markers in Japanese men without any history of cardiovascular disease: comparison with the fibrosis-4 score. J Atheroscler Thromb. 2021;28(5):524–534.
  • Cicero AFG, Gitto S, Fogacci F, et al. Fatty liver index is associated to pulse wave velocity in healthy subjects: data from the brisighella heart study. Eur J Intern Med. 2018;53:29–33.
  • Röhricht M, Paschke K, Sack P, et al. Phosphatidylethanol reliably and objectively quantifies alcohol consumption in adolescents and young adults. Alcohol Clin Exp Res. 2020;44(11):2177–2186.